XmAb®7195 is a humanized antibody that targets IgE and co-engages CD32b with our XmAb® γRIIb Fc domain for the treatment of asthma and allergy. By targeting only a specific B-cell population implicated in disease (IgE+ B cells) for engagement by our γRIIb Fc domain, XmAb®7195 inhibits the pathogenic over-production of IgE without affecting IgG production from bystander B cells. In addition, its binding affinity to IgE has been improved ten-fold compared to marketed anti-IgE antibodies using Xencor’s proprietary Fv platform. XmAb®7195 therefore sequesters soluble IgE to further suppress the allergic disease pathway. XmAb®7195 is in preclinical development.